ClinicalTrials.gov
ClinicalTrials.gov Menu

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00790010
Recruitment Status : Active, not recruiting
First Posted : November 13, 2008
Last Update Posted : February 1, 2018
Sponsor:
Collaborators:
Genentech, Inc.
Bristol-Myers Squibb
Information provided by (Responsible Party):
F. Stephen Hodi, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2018
  Estimated Study Completion Date : December 2018